Pfizer, Arvinas and breast cancer
Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...
A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage ...
Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results